A Survey Study on Clinicians' Rationale and Attitude Towards the Prescription of Antipsychotic Polypharmacy in the East Perth Metropolitan Area in Western Australia
- PMID: 37064723
- PMCID: PMC10098027
- DOI: 10.7759/cureus.37234
A Survey Study on Clinicians' Rationale and Attitude Towards the Prescription of Antipsychotic Polypharmacy in the East Perth Metropolitan Area in Western Australia
Abstract
Objective Patients challenging refractory and residual psychotic symptoms have led to the concomitant use of combined antipsychotics, which was later introduced and labelled 'antipsychotic polypharmacy' (APP). Many clinicians have become somewhat hesitant to adjust psychotropic medication dosages, resulting in a higher dose and combination prescription of antipsychotics and only achieving modest success. This study examines and investigates clinician perspectives and the rationale for the prescription of antipsychotic polypharmacy. Methods A structured questionnaire designed to reflect 15 target-directed questions evaluating clinicians' attitudes and rationale on antipsychotic polypharmacy prescription was administered from November to December 2022. Information was obtained from inpatient and outpatient prescribers (psychiatric consultants) in two government-funded psychiatric facilities and outpatient clinics in the East Perth Metropolitan Area in Western Australia. Results After exclusion, a total of 45 participants' responses were analysed. These results suggest a higher frequency of questions relating to the prescription of APP based on previous prescribers' consultation and recommendation from a prior treating team; senior nurses' pressure impacting clinicians' decisions on APP perception; and the patient's risk of aggression impacting the clinician's rationale for the prescription of APP. Conclusions Clinicians' rationale and attitude towards the prescription of APP are mostly influenced by recommendations from prior treatment teams or consultations and patients' risk for aggression without compromising practice guidelines. Our findings also highlight the need to evaluate prescribers' attitudes and how it presents an opportunity to enhance patients' holistic outcomes.
Keywords: antipsychotic polypharmacy (apps); clinicians prescribing rationale; prescribers attitude; prescribing practice; prescription of antipsychotic polypharmacy.
Copyright © 2023, Ajayi et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Similar articles
-
The hidden magnitude of polypharmacy: using defined daily doses and maximum licensed daily doses to measure antipsychotic load.Int J Clin Pharm. 2019 Dec;41(6):1642-1651. doi: 10.1007/s11096-019-00930-3. Epub 2019 Nov 1. Int J Clin Pharm. 2019. PMID: 31677120
-
Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior.Schizophr Res. 2011 Sep;131(1-3):58-62. doi: 10.1016/j.schres.2011.02.016. Epub 2011 Mar 21. Schizophr Res. 2011. PMID: 21419603 Free PMC article.
-
Attitudes towards and rationale for antipsychotic polypharmacy among psychiatrists in Nigeria: Characteristics associated with high reported antipsychotic polypharmacy.Psychiatry Res. 2017 Feb;248:134-139. doi: 10.1016/j.psychres.2016.12.032. Epub 2016 Dec 27. Psychiatry Res. 2017. PMID: 28063386
-
Polypharmacy Management of Antipsychotics in Patients with Schizophrenia.Medicina (Kaunas). 2022 Nov 3;58(11):1584. doi: 10.3390/medicina58111584. Medicina (Kaunas). 2022. PMID: 36363541 Free PMC article. Review.
-
Antipsychotic polypharmacy in schizophrenia: benefits and risks.CNS Drugs. 2011 May;25(5):383-99. doi: 10.2165/11587810-000000000-00000. CNS Drugs. 2011. PMID: 21476610 Review.
References
LinkOut - more resources
Full Text Sources